Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07112196 · ClinicalTrials.gov registry record · Phase 2
Visugromab in Cachexia International Trial
A Phase 2 study of Cancer-associated Cachexia, sponsored by CatalYm.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 518
- Enrollment target
- 1
- Study location
NCT07112196: Recruiting Phase 2 study of Cancer-associated Cachexia, sponsored by CatalYm.
NCT07112196 is a Phase 2 study of Cancer-associated Cachexia that is actively recruiting participants, run by CatalYm. The registered enrollment target is 518 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (289% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07112196, a Phase 2 study of Cancer-associated Cachexia, is actively recruiting participants, sponsored by CatalYm.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 518 participants
- Enrollment target
- 1
- Study location
Study Summary
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Visugromab (CTL-002)
Study Locations (1)
Florida
- Mid Florida Hematology and Oncology Centers - Orange City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2026-01 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
What NCT07112196 shows while recruiting
NCT07112196 is an interventional study that assigns participants to a tested intervention. The registered 518 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (289% higher).
The record links to 1 condition, with Cancer-associated Cachexia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07112196 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07112196 about?
NCT07112196 is a clinical study titled "Visugromab in Cachexia International Trial". A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better...
What is the current status of trial NCT07112196?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 518 participants. The study started on 2026-01. Estimated completion is 2030-12.
What conditions does trial NCT07112196 study?
This clinical trial studies the following conditions: Cancer-associated Cachexia.
What interventions are being tested in trial NCT07112196?
The interventions under investigation include: Placebo (DRUG), Visugromab (CTL-002) (DRUG).
Who is sponsoring clinical trial NCT07112196?
This trial is sponsored by CatalYm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07112196 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07112196's enrollment target sits among peer trials
518 67th of 2000 higher than 1,934 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04524871 · 518 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- NCT05676450 · 517 participants · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia